3T Biosciences Announces Appointments of Behzad Kharabi, M.D., as Chief Medical Officer, and Parker Institute for Cancer Immunotherapy (PICI) CEO Karen Knudsen, MBA, Ph.D., to Board of Directors

Kharabi led development of CD19 CAR-T therapy TECARTUS®; brings extensive cell and gene therapy expertise to guide 3T’s bispecific T-cell engager programs into the clinic Knudsen oversees more than 100 immunotherapy studies at PICI; adds deep translational oncology insight to help shape 3T’s scientific and clinical strategy SOUTH SAN FRANCISCO,… The post 3T Biosciences Announces Appointments of Behzad Kharabi, M.D., as Chief Medical Officer, and Parker Institute for Cancer Immunotherapy (PICI) CEO Karen Knudsen, MBA, Ph.D., to Board of Directors first appeared on 3T Biosciences .